Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Shigellosis Clinical Presentation

  • Author: Joyann A Kroser, MD, FACP, FACG, AGAF; Chief Editor: BS Anand, MD  more...
 
Updated: Jun 22, 2016
 

History

See the list below:

  • Acute bloody diarrhea[26]
  • Crampy abdominal pain
  • Tenesmus
  • Passage of mucus
  • Fever (1-3 d after exposure)
  • Occasionally vomiting (35% prevalence)
  • Self-limited course (3 d to 1 wk and rarely lasts as long as 1 mo)
Next

Physical

See the list below:

  • Lower abdominal tenderness
  • Normal or increased bowel sounds
  • Dehydration (occasional)
Previous
Next

Causes

See the list below:

  • S sonnei and S flexneri cause 90% of the cases of shigellosis.
  • S dysenteriae has produced epidemic shigellosis.
Previous
 
 
Contributor Information and Disclosures
Author

Joyann A Kroser, MD, FACP, FACG, AGAF Adjunct Clinical Associate Professor of Medicine, Gastroenterology, and Hepatology, Drexel University College of Medicine; Adjunct Professor of Medicine, Temple University School of Medicine

Joyann A Kroser, MD, FACP, FACG, AGAF is a member of the following medical societies: American College of Physicians, Alpha Omega Alpha, Crohn's and Colitis Foundation of America, American College of Gastroenterology, American Gastroenterological Association, American Medical Association, American Society for Gastrointestinal Endoscopy, Pennsylvania Medical Society, Phi Beta Kappa, Philadelphia County Medical Society

Disclosure: Nothing to disclose.

Coauthor(s)

Amandeep Singh, MBBS Resident Physician, Department of Internal Medicine, Crozer Chester Medical Center

Amandeep Singh, MBBS is a member of the following medical societies: American Academy of Family Physicians, American College of Gastroenterology, American College of Physicians

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Aaron Glatt, MD Chief Administrative Officer, Executive Vice President, Mercy Medical Center, Catholic Health Services of Long Island

Aaron Glatt, MD is a member of the following medical societies: American College of Chest Physicians, American Association for Physician Leadership, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Association, American Society for Microbiology, American Thoracic Society, American Venereal Disease Association, Infectious Diseases Society of America, International AIDS Society, Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Chief Editor

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Additional Contributors

Ronnie Fass, MD, FACP, FACG Chief of Gastroenterology, Head of Neuroenteric Clinical Research Group, Southern Arizona Veterans Affairs Health Care System; Professor of Medicine, Division of Gastroenterology, University of Arizona School of Medicine

Ronnie Fass, MD, FACP, FACG is a member of the following medical societies: American College of Gastroenterology, American College of Physicians-American Society of Internal Medicine, American Gastroenterological Association, American Neurogastroenterology and Motility Society, American Society for Gastrointestinal Endoscopy, Israeli Medical Association

Disclosure: Received grant/research funds from Takeda Pharmaceuticals for conducting research; Received consulting fee from Takeda Pharmaceuticals for consulting; Received honoraria from Takeda Pharmaceuticals for speaking and teaching; Received consulting fee from Vecta for consulting; Received consulting fee from XenoPort for consulting; Received honoraria from Eisai for speaking and teaching; Received grant/research funds from Wyeth Pharmaceuticals for conducting research; Received grant/research funds f.

References
  1. Mellouk N, Enninga J. Cytosolic access of intracellular bacterial pathogens: the Shigella paradigm. Front Cell Infect Microbiol. 2016. 6:35. [Medline].

  2. Killackey SA, Sorbara MT, Girardin SE. Cellular aspects of Shigella pathogenesis: focus on the manipulation of host cell processes. Front Cell Infect Microbiol. 2016. 6:38. [Medline].

  3. Agaisse H. Molecular and cellular mechanisms of Shigella flexneri dissemination. Front Cell Infect Microbiol. 2016. 6:29. [Medline].

  4. Nuesch-Inderbinen M, Heini N, Zurfluh K, Althaus D, Hachler H, Stephan R. Shigella antimicrobial drug resistance mechanisms, 2004-2014. Emerg Infect Dis. 2016 Jun. 22 (6):1083-5. [Medline].

  5. Dupont HL, Edelman R, Kimmey M. Infectious diarrhea: from E coli to Vibrio. Patient Care. 1990. 30:18-43.

  6. Al-Abri SS, Beeching NJ, Nye FJ. Traveller's diarrhoea. Lancet Infect Dis. 2005 Jun. 5(6):349-60. [Medline].

  7. Moralez EI, Lofland D. Shigellosis with resultant septic shock and renal failure. Clin Lab Sci. 2011 Summer. 24(3):147-52. [Medline].

  8. Khan WA, Griffiths JK, Bennish ML. Gastrointestinal and extra-intestinal manifestations of childhood shigellosis in a region where all four species of Shigella are endemic. PLoS One. 2013. 8(5):e64097. [Medline].

  9. Khan WA, Griffiths JK, Bennish ML. Gastrointestinal and extra-intestinal manifestations of childhood shigellosis in a region where all four species of Shigella are endemic. PLoS One. 2013. 8(5):e64097. [Medline]. [Full Text].

  10. Bennish ML. Potentially lethal complications of shigellosis. Rev Infect Dis. 1991 Mar-Apr. 13 Suppl 4:S319-24. [Medline].

  11. Bennish ML, Azad AK, Yousefzadeh D. Intestinal obstruction during shigellosis: incidence, clinical features, risk factors, and outcome. Gastroenterology. 1991 Sep. 101(3):626-34. [Medline].

  12. Azad MA, Islam M, Butler T. Colonic perforation in Shigella dysenteriae 1 infection. Pediatr Infect Dis. 1986 Jan-Feb. 5(1):103-4. [Medline].

  13. Martin T, Habbick BF, Nyssen J. Shigellosis with bacteremia: a report of two cases and a review of the literature. Pediatr Infect Dis. 1983 Jan-Feb. 2(1):21-6. [Medline].

  14. Struelens MJ, Patte D, Kabir I, Salam A, Nath SK, Butler T. Shigella septicemia: prevalence, presentation, risk factors, and outcome. J Infect Dis. 1985 Oct. 152(4):784-90. [Medline].

  15. Morduchowicz G, Huminer D, Siegman-Igra Y, Drucker M, Block CS, Pitlik SD. Shigella bacteremia in adults. A report of five cases and review of the literature. Arch Intern Med. 1987 Nov. 147(11):2034-7. [Medline].

  16. Keddy KH, Sooka A, Crowther-Gibson P, et al. Systemic shigellosis in South Africa. Clin Infect Dis. 2012 May. 54(10):1448-54. [Medline].

  17. Keusch GT, Bennish ML. Shigellosis: recent progress, persisting problems and research issues. Pediatr Infect Dis J. 1989 Oct. 8(10):713-9. [Medline].

  18. Butler T, Islam MR, Bardhan PK. The leukemoid reaction in shigellosis. Am J Dis Child. 1984 Feb. 138(2):162-5. [Medline].

  19. Khan WA, Dhar U, Salam MA, Griffiths JK, Rand W, Bennish ML. Central nervous system manifestations of childhood shigellosis: prevalence, risk factors, and outcome. Pediatrics. 1999 Feb. 103(2):E18. [Medline].

  20. Avital A, Maayan C, Goitein KJ. Incidence of convulsions and encephalopathy in childhood Shigella infections. Survey of 117 hospitalized patients. Clin Pediatr (Phila). 1982 Nov. 21(11):645-8. [Medline].

  21. Simon DG, Kaslow RA, Rosenbaum J, Kaye RL, Calin A. Reiter's syndrome following epidemic shigellosis. J Rheumatol. 1981 Nov-Dec. 8(6):969-73. [Medline].

  22. Siegler RL. The hemolytic uremic syndrome. Pediatr Clin North Am. 1995 Dec. 42(6):1505-29. [Medline].

  23. Murphy TV, Nelson JD. Shigella vaginitis: report of 38 patients and review of the literature. Pediatrics. 1979 Apr. 63(4):511-6. [Medline].

  24. Tobias JD, Starke JR, Tosi MF. Shigella keratitis: a report of two cases and a review of the literature. Pediatr Infect Dis J. 1987 Jan. 6(1):79-81. [Medline].

  25. Rubenstein JS, Noah ZL, Zales VR, Shulman ST. Acute myocarditis associated with Shigella sonnei gastroenteritis. J Pediatr. 1993 Jan. 122(1):82-4. [Medline].

  26. Kroser JA, Metz DC. Evaluation of the adult patient with diarrhea. Prim Care. 1996 Sep. 23(3):629-47. [Medline].

  27. Banerjee S, LaMont JT. Treatment of gastrointestinal infections. Gastroenterology. 2000 Feb. 118(2 Suppl 1):S48-67. [Medline].

  28. Murphy GS, Bodhidatta L, Echeverria P, et al. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann Intern Med. 1993 Apr 15. 118(8):582-6. [Medline].

  29. Wolf DC, Gianella RA. Invasive pathogens. Consultations in Gastroenterology. 1996. 381-384.

  30. Sivapalasingam S, Nelson JM, Joyce K, et al. High prevalence of antimicrobial resistance among Shigella isolates in the United States tested by the National Antimicrobial Resistance Monitoring System from 1999 to 2002. Antimicrob Agents Chemother. 2006 Jan. 50(1):49-54. [Medline].

  31. Vinh H, Anh VT, Anh ND, Campbell JI, Hoang NV, Nga TV, et al. A multi-center randomized trial to assess the efficacy of gatifloxacin versus ciprofloxacin for the treatment of shigellosis in Vietnamese children. PLoS Negl Trop Dis. 2011 Aug. 5(8):e1264. [Medline]. [Full Text].

  32. Policar M. Shigellosis. Ferri's Clinical Advisor: Instant Diagnosis and Treatment. 2005. 752-754.

  33. Gu B, Ke X, Pan S, Cao Y, Zhuang L, Yu R, et al. Prevalence and trends of aminoglycoside resistance in Shigella worldwide, 1999-2010. J Biomed Res. 2013 Mar. 27(2):103-15. [Medline]. [Full Text].

  34. Taneja N. Changing epidemiology of shigellosis and emergence of ciprofloxacin-resistant Shigellae in India. J Clin Microbiol. 2007 Feb. 45(2):678-9. [Medline].

  35. Heiman KE, Karlsson M, Grass J, Howie B, Kirkcaldy RD, Mahon B, et al. Notes from the field: Shigella with decreased susceptibility to azithromycin among men who have sex with men - United States, 2002-2013. MMWR Morb Mortal Wkly Rep. 2014 Feb 14. 63(6):132-3. [Medline].

  36. Lewis R. Azithromycin Not Effective Against All Shigella Infections. Available at http://www.medscape.com/viewarticle/820607. Accessed: February 23, 2014.

  37. Lübbert C. Antimicrobial therapy of acute diarrhoea: a clinical review. Expert Rev Anti Infect Ther. 2016. 14 (2):193-206. [Medline].

  38. Li YL, Tewari D, Yealy CC, Fardig D, M'ikanatha NM. Surveillance for travel and domestically acquired multidrug-resistant human Shigella infections-Pennsylvania, 2006-2014. Health Secur. 2016 May-Jun. 14 (3):143-51. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.